Ingredion shares closed at US$97.91 after a mixed run that includes a 5 year gain but a weaker patch more recently, which puts the focus squarely on what the current price implies about the cash the business can generate. With that backdrop, the question for you is whether the recent share price leaves a reasonable margin between market expectations and the cash flows Ingredion is likely to produce.
- Over the past 5 years the stock has gained 25.9%, so any view on Ingredion today really hinges on whether that kind of long term outcome is in line with the cash flows investors are implicitly paying for.
- The planned US$3.6b acquisition of Tate & Lyle can reshape Ingredion's mix toward texture and health focused ingredients, which may influence future cash generation through different growth expectations, margins and investment needs.
- What if you looked at Ingredion through its earnings instead? See why Ingredion's 10.4x P/E tells a different valuation story.
The stock's next move may depend on whether Ingredion's current share price is fully backed by the cash flows implied by a Discounted Cash Flow (DCF) style intrinsic value estimate.
If you want to cross check Ingredion against a wider set of ideas before committing fresh capital, a focused screen of 29 high quality undervalued stocks can be a useful next stop in your research process.
Is Ingredion Fairly Priced on Cash Flow?
The Discounted Cash Flow (DCF) model here looks at how much cash Ingredion could return to shareholders over time and then compares that stream to today’s price of US$97.91. Ingredion generated about $448 million of free cash flow over the last twelve months, and the model assumes cash generation recovers toward higher levels before settling into a gentler decline and then a relatively stable run rate over the next decade.
The projection path shows free cash flow easing back from near term strength rather than rising rapidly each year. This fits a business already producing meaningful cash rather than one relying on aggressive expansion assumptions. Because the US$3.6b Tate & Lyle deal is intended to push more of Ingredion’s portfolio into texture and health focused ingredients, the market appears to be treating that shift as broadly consistent with the cash flows implied by the DCF output. The Discounted Cash Flow (DCF) projections put Ingredion's estimated intrinsic value broadly in line with the current share price, so the stock does not screen as clearly cheap or clearly expensive on this lens alone. Find out what Ingredion could be worth using our Discounted Cash Flow (DCF) estimate.
The Ingredion Narrative: What Would Justify Today's Price?
Narratives pick up where the DCF puzzle leaves you, by spelling out which assumptions about Ingredion's future growth, profitability and earnings power would need to play out for the share price to move meaningfully higher or lower from here. These narratives sit on Simply Wall St's Community page. Each scenario ties a fair value estimate to a particular mix of potential catalysts and risks so you can track over time which version of Ingredion's story is getting closer to reality.
Community views on Ingredion are split between a patient growth story and a more cautious read on what the current price already reflects.
Bull case: 19% undervalued
"Continued mix shift toward Texture & Healthful Solutions, which has delivered nine consecutive quarters of net sales volume growth and an 18.7% operating margin in the most recent quarter discussed…"
Discover why this Narrative puts Ingredion at 19% undervalued.
Bear case: 11% overvalued
"The company continues to face price and mix headwinds from passing through lower corn and input costs to customers…"
Explore why this Narrative puts Ingredion at 11% overvalued.
The unanswered Ingredion question: who is steering it and what are they paid to aim for?
Cash flow models only tell you what the business might earn, not how the people in charge are rewarded for the choices they make with it. See who runs Ingredion and how they are paid.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com